WhenMoon
1 hour ago
From what I can see, Vyvanse IQVIA was 4.3 billion as of October 2024 according to Elite's Vyvanse launch press release. Generic Vyvanse entered the market in August 2023. By October 2023, generic was 71% market share. The shortage happened i early 2024, leading to brand reclaiming some market share, but since March 2024 brand market share has been trending down.
So while we don't know exact percentages at this moment, the 4.3 billion number was after generic had been in the market for 15 months, with generic claiming well over half the market share already in 3 months after launch.
WhenMoon
2 hours ago
True, however the assumption that Vyvanse market will get cut in half is way too pessimistic. Generic market share is currently sitting at around 75% so the most the IQVIA annual sales could even possibly decrease from future generic entry is around 25%, and even that would be if there was 0% branded market share. Given this I think mrwn2010's number's are feasible if not conservative. Reason being, that while the IQVIA annual sale numbers are not a 1 for 1 conversion in terms of potential revenue for Elite, due to the reasons you stated, the total IQVIA market should be estimated to be around 3.5 billion or even higher, not 2 billion, when factoring in decreases for generic entry.
My opinion.
jour_trader
4 hours ago
As much as I'd love this, I'm not sure the math works out as we haven't seen this for the Adderalls, the sibling to Vyvanse. If it were true, Adderall XR alone at a 13% market share would yield 150M+ in annualized rev. That's excluding the higher market share product of Adderall IR and all other products in portfolio.
I think you need to cut it in half again and maybe more so as total market includes significant portion of brand product for Vyvanse.
I think what hits (taking into pharmacy, logistics partners, etc) is about 5% of Adderall market for products recorded as Elite revenue.
Would really love to see otherwise. I'm guessing gross margins on Vyvanse will be much better too, so perhaps my expectations are too conservative, but fierce competition will be picking up too as API becomes more available in the long run.
Let's get that API machine going! I'm not a chemist, but did enjoy couple O Chem classes, would it even be feasibly possible for Elite to build out API mfg and be more vertically integrated? Perhaps this would be the best merger, with our API supplier, capture incremental margin and drive some real financial growrh as we take on our own distribution down road as well.
$2.00 or no deal
4 hours ago
Please give a thumbs up if you're going to take out a margin loan when we uplist to Nasdaq.
For me, I am going to MAX OUT a margin loan, but I would assume most shareholders won't do this.
However, if you are going to take out a margin loan of ANY size, please give a thumbs up.
Thanks.
As previous stated, I am going to MAX OUT a margin loan when we uplist to Nasdaq in the coming weeks/months.
$2.00 or no deal
5 hours ago
You realize it could be the EXACT opposite, right?
It could mean Elite's products are not selling, which is why they're still on the shelves.
Here's a few examples:
1. During covid, toilet paper was COMPLETELY out of stock at the majority of stores. Now was that because the product wasn't selling........or because it WAS selling, and not only was it selling, it was selling like HOT CAKES.
2. The Nintendo Switch 2 is currently experiencing high demand and is largely sold out at major retailers, both online and in physical stores. While some restocks have occurred, they are selling out quickly, especially online. Finding one in stock requires checking retailer websites frequently and potentially visiting physical stores.
Conclusion: According to you and the examples above, Elite's products are NOT selling very well..........if at all.
The one thing I know is sales are solid. I see Elite products in every pharmacy I float through.
mrwrn2010
6 hours ago
If we assume Vyvanse market gets cut by over half with generic entry, and if Elite can get close to Adderall market share....
Potential revenues off Vyvanse alone:
5% of 2B market - $100,000,000
10% - $200,000,000
15% - $300,000,000
NASDAQ2020
7 hours ago
✅️Elite Pharma (ELTP) Catalyst :✅️
We could check 5-10 of these by July 1st
✅️ 1. Cash Flow Positive
✅️ 2. Purchase building housing their cGMP registered facility for research, development, manufacturing and packaging of pharmaceutical products.
✅️ 3. Adderall IR $421.7 Million IMS market Approved and Launched
✅️ 4. Adderall XR $865 Million IMS market Approved and Launched
✅️ 5. Double digit quarterly revenues in millions
✅️ 6. Create in house marketing and distribution: Kirko Kirkov, Doug Plassche and their teams
✅️ 7. DEA increases manufacturing quotas for Adderall & Vyvance
✅️ 8. Generic OxyContin - FIRST TO FILE FDA Aug 17, 2023 $720 Million
✅️ 9. Generic Vyvanse - $4.3 BILLION - FDA submission Dec 2023
✅️ 10. FDA Acceptance of Generic OxyContin Sept 2023
✅️ 11. Lease additional manufacturing space and storage vault for new Needle Mover ANDAs - Jan 2024
__12. Obtain Full ownership of Adderall IR $ 421.7 Million from MIKAH
__13. Obtain Full ownership of Adderall XR $ 865 Million from MIKAH
✅️ 14. Generic Methotrexate Antimetabolite- Approval
✅️ 15. Launch generic Methotrexate $63 Million
✅️ 16. $50+ million in yearly revenues
✅️ 17. Lowest PE ratio for OTC Healthcare sector
✅️ 18. Become the ONLY company showing rapid growth on the OTC while being profitable
✅️ 19. Put Opioids back on the Table- due to reduced risk of opioid litigation
✅️ 20. Receive Analyst Coverage - Upgrade to Market Outperform - Zacks Investment Research
✅️ 21. International Distribution - partnership Approval by Israeli Ministry of Health for European distribution License and Distribution Agreement by and between Elite Pharmaceuticals, Inc. and Dexcel Ltd.
✅️ 22. Generic IR Adderall® Receives Marketing Approval From The Israeli Ministry Of Health Oct 2024
✅️ 23. Final Approval of New Manufacturing Facility/Expansion
__ 24. Generate revenues over $20 million/quarter —- Imminent
__ 25. Generate revenues over $30 million/quarter ----Imminent
__ 26. Generate revenues over $40 million/quarter ----Possible
__ 27. Generate revenues over $50 million/quarter
❓️ 28. Double output of manufacturing and packaging facilities —-Imminent
✅️ 29. Launch approved generic Tylenol with Codeine $47 Million
✅️ 30. Launch approved generic Norco - hydrocodone acetaminophen IMS $300 Million
✅️ 31. Launch approved generic Percocet - oxycodone acetaminophen IMS $317 Million
__ 32. Launch approved generic Dolophine - methadone HCL tablets IMS $30 Million
__ 33. Dopamine Agonist Approval (probably Requip XL or Mirapex ER). $12 Million
✅️ 34. Generic Vyvanse (The Golden Goose) Approval $4.3 Billion
__ 35. Indian Research and Development agreement
__ 36. Positive BE Study for Concerta CNS Stimulant $1.16 Billion
✅️ ✅️ ✅️ 37. LAUNCH $4.3 Billion Generic Vyvanse Dec 2024
__38. Generic Concerta- FDA submission $1.16 Billion
__39. Launch Adderall IR in Israel —War may delay
__40. 100 million in yearly revenues —-2025/2026
__41. Generic OxyContin Approval $720 Million
✅️ 42. Accord prevail over Purdue in Generic OxyContin infringement suit - Dec 30, 2024
https://cafc.uscourts.gov/opinions-orders/23-1953.OPINION.12-30-2024_2443222.pdf
__43. Elite prevail over Purdue in Generic OxyContin infringement suit.
https://www.pacermonitor.com/public/case/51356241/PURDUE_PHARMA_LP_et_al_v_ELITE_LABORATORIES_INC,_et_al
__43. Launch generic OxyContin $720 Million
__44. Positive BE on NDA Unique ADF opioid - 90% cheaper than ADF without Naltrexone
__45. Resume R&D on SequestOx Abuse Deterrent Oxycodone
__46. $200 million in yearly revenue
__47. Patented NDA Unique ADF (w/o naltrexone) drug C in SequestOx reformulation trial
__48. Undisclosed Mikah ANDA(s)
__49. Undisclosed ANDAs/NDAs
__50. Generic Concerta Launch $1.16 Billion
__51. DollarLand PPS ——2025-------
__52. Uplist to NASDAQ exchange
__53. M&A advisory firm selected for buyout
__54. Perform Business Valuation
__55. Develop strategy set for sale of business
__56. Prepare marketing materials for sale
__57. The advisory firm begins to identify and approach potential buyers.
__58. Management teams present the company's strengths and growth potential to interested buyers
__59. Site visits by potential Buyers to inspect and meet management.
__60. Begin Buyout Negotiations
__61. Buyout offer/s
__62. Buyer Identified
__63. Purchase Definitive Agreement
__64. Buyout Vote of Board of Directors
__65. Halt Trading
__66. Shareholder vote on offer
__67. Necessary regulatory approvals are obtained for transfer of ownership
__68. Buyout Closing Completed —$$$$$$$$$$$
__69. Vegas BABY !!!!! 🎰
jour_trader
1 day ago
Dexcel has a lot ont heir plate now with the Israel/Iran conflict, but wonder what else is cooking up besides Adderalls & Vyvanse. Geographies beyond Israel or other products?
Per last cc, "Along the way, they've mentioned that they're interested is Amphetamine ER and Vyvanse and other things. But one thing at a time, let's go through one process successfully, then step and repeat."